Findings lay groundwork for human clinical trial planned for August 2016
A new scientific study has identified why colorectal cancer cells depend on a specific nutrient, and a way to starve them of it. Over one million men and women are living with colorectal cancer in the United States. The National Cancer Institute estimates 4.5% of all men and women will be diagnosed with the cancer during their lifetime, making it the third most common non-skin cancer.
In the study published online in Nature Communications, researchers showed how certain colorectal cancer cells reprogram their metabolism using glutamine, a non-essential amino acid. Many cancer cells rely on glutamine to survive. How they become so dependent on the molecule is hotly debated in the field.
Researchers studied a subset of colorectal cancer cells containing a genetic mutation called PIK3CA. This mutation is located in a gene critical for cell division and movement, and is found in approximately one third of all colorectal cancers. The mutation is also the most commonly identified genetic mutation across all cancers, making the results of the study universally appealing.
Researchers were interested in determining whether or not the common PIK3CA mutation contributes to changes in cancer cell metabolism, such as how nutrients like glutamine are processed. Normally, glutamine is broken down by cancer cells into several other molecules with the help of specific enzymes. This complicated system helps produce adenosine triphosphate, the energy currency of all cells, and other molecules critical for colorectal cancer cell growth.
The researchers found that colorectal cells with the PIK3CA mutation broke down significantly more glutamine than cells without the mutation. The researchers identified several enzymes involved in the process that are more active in the mutant cancer cells than in other cell types, explaining the increased need for glutamine. These enzymes become overactive in the mutant cancer cells due to a cascade of signals led by the protein encoded by mutant PIK3CA gene. This finding represents a novel and important link between the common PIK3CA mutation and altered glutamine metabolism in cancer cells.
Zhenghe John Wang, PhD, professor of genetics and genome sciences and co-leader of the Cancer Genetics Program at Case Western Reserve University School of Medicine helped lead the study. “In layman’s terms, we discovered that colon cancers with PIK3CA oncogenic mutations are addicted to glutamine, a particular nutrient for cancer cells. We also demonstrated that these cancers can be starved to death by depriving glutamine with drugs.”
When the researchers lowered the amount of glutamine available to mutant cancer cells growing in laboratory dishes, the cancer cells died. This discovery led the team to investigate the effects of blocking glutamine availability in mice with colorectal cancer tumors containing the common PIK3CA mutation. Wang and colleagues found that exposing these mice to a compound that blocks glutamine metabolism consistently suppressed tumor growth. They did not observe the same effect on tumors without the mutation. Together, these results provide a promising new therapeutic avenue to suppress growth of colorectal tumors with the PIK3CA mutation. The researchers have filed a patent application based on the unique mechanism of tumor suppression they have identified and the work is available for licensing.
“This study provides the basis for a colon cancer treatment clinical trial that will be started in the summer at the University Hospitals Seidman Cancer Center,” according to Neal Meropol, MD, Dr. Lester E. Coleman, Jr. Professor of Cancer Research and Therapeutics, chief of the division of hematology and oncology, and principal investigator for the trial. The phase I/II study will test the effects of a glutamine metabolism inhibitor in patients with advanced colorectal tumors.
Learn more: Case Western Reserve University researchers block common colon cancer tumor type in mice
The Latest on: Colorectal cancers
[google_news title=”” keyword=”colorectal cancers” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Colorectal cancers
- Early age onset colorectal cancer is on the riseon April 27, 2024 at 2:10 pm
Why are early-age-onset colorectal cancer (EAO-CRC) rates rising? What can young adults and the healthcare industry do to lower the rates?
- Clue to Aspirin, Colon Cancer Link; New Lutathera Approval; AI & Electronic Recordson April 26, 2024 at 12:51 pm
Integrating AI into electronic messaging systems may help relieve physician burden and improve patient education but still requires a "physician in the loop" as a backstop for errors in messaging. ( ...
- How body shape influences colorectal cancer riskon April 25, 2024 at 9:52 pm
Study reveals that specific body shape phenotypes, such as general obesity and central obesity, significantly increase the risk of colorectal cancer, suggesting distinct molecular pathways for ...
- Colorectal cancer rates have increased in those under 55on April 25, 2024 at 8:24 am
The rates of colon and rectal cancer in people under 55 continue to rise. Now millennials get colon cancer twice as much as other adults, and rectal cancer four times as much.
- Symptoms That May Signal Early Colon Canceron April 25, 2024 at 6:31 am
Diagnosing colon cancer early is important so that it can be treated most effectively. Paying attention to any possible symptoms is key. While there may be symptoms of early colon cancer, sometimes ...
- Young adults at highest risk of being diagnosed with colorectal canceron April 24, 2024 at 1:44 pm
Getting better sleep, exercising, diversifying your microbiome and getting regular screenings can help reduce the risks of colorectal cancer.
- Study: Daily Aspirin May Help Boost the Immune System and Prevent Spread of Colorectal Canceron April 24, 2024 at 9:18 am
Taking aspirin may help prevent or delay the progression of colorectal cancer, a new study published in the journal 'Cancer' has found. Colorectal cancer rates among people under 50 are going up by 2% ...
- Mini-colons advance colorectal cancer researchon April 24, 2024 at 8:00 am
In a breakthrough for cancer research, scientists at EPFL have created lab-grown mini-colons that can accurately mimic the development of colorectal tumors, offering a powerful new tool for studying ...
- Aspirin boosts immune response against colon cancer, study showson April 24, 2024 at 7:02 am
Tissue samples from aspirin users showed less cancer spread to the lymph nodes, and more aggressive activity of immune cells against tumors, the researchers said. In the lab, they discovered that ...
- Balancing hope and reality: The promise and peril of blood-based colorectal cancer screeningon April 24, 2024 at 1:30 am
A simple blood test to detect colorectal cancer sounds amazing. But unlike colonoscopy, a blood test can't remove precancerous polyps.
via Bing News